Suppr超能文献

联合经动脉化疗栓塞和立体定向体部放疗后肝癌患者完全组织病理学应答率高。

High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy.

机构信息

Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Munich 81675, Germany.

Department of Radiotherapy and Radiation Oncology, University of Salzburg, Salzburg 5020, Austria.

出版信息

World J Gastroenterol. 2021 Jun 28;27(24):3630-3642. doi: 10.3748/wjg.v27.i24.3630.

Abstract

BACKGROUND

Liver transplantation (LT) presents a curative treatment option in patients with early stage hepatocellular carcinoma (HCC) who are not eligible for resection or ablation therapy. Due to a risk of up 30% for waitlist drop-out upon tumor progression, bridging therapies are used to halt tumor growth. Transarterial chemoembolization (TACE) and less commonly stereotactic body radiation therapy (SBRT) or a combination of TACE and SBRT, are used as bridging therapies in LT. However, it remains unclear if one of those treatment options is superior. The analysis of explant livers after transplantation provides the unique opportunity to investigate treatment response by histopathology.

AIM

To analyze histopathological response to a combination of TACE and SBRT in HCC in comparison to TACE or SBRT alone.

METHODS

In this multicenter retrospective study, 27 patients who received liver transplantation for HCC were analyzed. Patients received either TACE or SBRT alone, or a combination of TACE and SBRT as bridging therapy to liver transplantation. Liver explants of all patients who received at least one TACE and/or SBRT were analyzed for the presence of residual vital tumor tissue by histopathology to assess differences in treatment response to bridging therapies. Statistical analysis was performed using Fisher-Freeman-Halton exact test, Kruskal-Wallis and Mann-Whitney- tests.

RESULTS

Fourteen patients received TACE only, four patients SBRT only, and nine patients a combination therapy of TACE and SBRT. There were no significant differences between groups regarding age, sex, etiology of underlying liver disease or number and size of tumor lesions. Strikingly, analysis of liver explants revealed that almost all patients in the TACE and SBRT combination group (8/9, 89%) showed no residual vital tumor tissue by histopathology, whereas TACE or SBRT alone resulted in significantly lower rates of complete histopathological response (0/14, 0% and 1/4, 25%, respectively, value < 0.001).

CONCLUSION

Our data suggests that a combination of TACE and SBRT increases the rate of complete histopathological response compared to TACE or SBRT alone in bridging to liver transplantation.

摘要

背景

肝移植(LT)为早期肝细胞癌(HCC)患者提供了一种有治愈可能的治疗选择,这些患者不适合接受切除术或消融治疗。由于肿瘤进展导致 30%的等待名单脱落风险,因此使用桥接治疗来阻止肿瘤生长。经动脉化疗栓塞术(TACE)和较少使用的立体定向体放射治疗(SBRT)或 TACE 和 SBRT 的联合治疗,被用作 LT 的桥接治疗。然而,目前尚不清楚这些治疗方法中哪一种更具优势。移植后肝脏的分析提供了通过组织病理学研究治疗反应的独特机会。

目的

分析 TACE 和 SBRT 联合治疗 HCC 与单独 TACE 或 SBRT 相比的组织病理学反应。

方法

在这项多中心回顾性研究中,分析了 27 例因 HCC 接受肝移植的患者。患者接受单独 TACE 或 SBRT 治疗,或 TACE 和 SBRT 的联合治疗作为肝移植的桥接治疗。对所有接受至少一次 TACE 和/或 SBRT 的患者的肝移植标本进行组织病理学分析,以评估桥接治疗的治疗反应差异。统计分析采用 Fisher-Freeman-Halton 精确检验、Kruskal-Wallis 和 Mann-Whitney-U 检验。

结果

14 例患者仅接受 TACE 治疗,4 例患者仅接受 SBRT 治疗,9 例患者接受 TACE 和 SBRT 的联合治疗。各组间在年龄、性别、基础肝病病因或肿瘤病变的数量和大小方面无显著差异。值得注意的是,对肝移植标本的分析表明,TACE 和 SBRT 联合治疗组的几乎所有患者(8/9,89%)的组织病理学均未见残留的有活力的肿瘤组织,而单独 TACE 或 SBRT 治疗组的完全组织病理学反应率显著降低(分别为 0/14,0%和 1/4,25%, 值<0.001)。

结论

与单独 TACE 或 SBRT 桥接相比,我们的数据表明 TACE 和 SBRT 的联合治疗可提高完全组织病理学反应率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/293b/8240047/d986638c18e5/WJG-27-3630-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验